Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Globe Newswire 11-Nov-2025 9:00 AM

SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences.

• The 7^th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.
  
  
  
  
• The 37^th Annual Piper Sandler Healthcare Conference with a fireside chat on Tuesday, Dec. 2, 2025, at 12:00 pm ET.

The presentations will be available through live audio webcast links in the investor information section of Myriad's website at investor.myriad.com. 

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor Contact 

Matt Scalo 

(801) 584-3532 

IR@myriad.com 

Media Contact 

Kate Schraml

(224) 875-4493

PR@myriad.com